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Abstract
Purpose Older people with dementia are at risk of adverse events associated with potentially inappropriate prescribing. Aim: to
describe (1) how international tools designed to identify potentially inappropriate prescribing have been used in studies of older
people with dementia, (2) the prevalence of potentially inappropriate prescribing in this cohort and (3) advantages/disadvantages
of tools
Methods Systematic literature review, designed and reported according to the Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P). MEDLINE, EMBASE, PsychInfo, CINAHL, the Cochrane Library, the Social Science
Citation Index, OpenGrey, Base, GreyLit, Mednar and the National Database of Ageing Research were searched in April 2016 for
studies describing the use of a tool or criteria to identify potentially inappropriate prescribing in older people with dementia.
Results Three thousand three hundred twenty-six unique papers were identified; 26 were included in the review. Eight studies
used more than one tool to identify potentially inappropriate prescribing. There were variations in how the tools were applied.
The Beers criteria were the most commonly used tool. Thirteen of the 15 studies using the Beers criteria did not use the full tool.
The prevalence of potentially inappropriate prescribing ranged from 14 to 74% in older people with dementia. Benzodiazepines,
hypnotics and anticholinergics were the most common potentially inappropriately prescribed medications.
Conclusions Variations in tool application may at least in part explain variations in potentially inappropriate prescribing across
studies. Recommendations include a more standardised tool usage and ensuring the tools are comprehensive enough to identify
all potentially inappropriate medications and are kept up to date.
Keywords Potentially inappropriate prescribing . Dementia . Older people . Polypharmacy
Introduction
It is estimated that 47 million people worldwide are living with
dementia, and this is set to increase to more than 131 million by
2050 [1]. People with dementia experience higher levels of co-
morbidities and may receive on average more medications than
their cognitively intact counterparts [2]. They may also receive
suboptimal care that includes poor pain control [3, 4] and pre-
scribing of potentially inappropriate medications (PIMs) [5].
Prescribing is potentially inappropriate where there are
drug–disease or drug–drug interactions, where the risks of a
medication outweigh the benefits, where there is a lack of
evidence for a medication or where time to benefit of treat-
ment exceeds an individual’s life expectancy [6]. Potentially
inappropriate prescribing (PIP) has been associated with an
increased risk of adverse drug events (ADEs), hospitalisation,
mortality and lower quality of life in older people with and
without dementia [7, 8].
Many tools have been developed to identify PIP in older
people for use in research and in clinical settings. An overview
of published tools identified 46 different tools for identifying
PIP, of which 36 were developed for use with older people and
6 for use in long-term care settings [9]. The most commonly
used tool is the Beers criteria which were first published in
1991 and have been regularly updated since [10–14]. They
include lists of medications considered inappropriate for older
people in general and also provide a list of PIMs for specific
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conditions such as dementia and Parkinson’s disease. Another
commonly used tool is the STOPP START criteria which in
addition to identifying medications that may need to be
stopped also identify where there may be a potential under-
use of medications [15, 16]. The content of the different tools
varies, and there is a lack of consensus about what medica-
tions are inappropriate and under what circumstances [17, 18].
Several studies have been published that describe and com-
pare tools to identify PIP; however, they have focused on
identifying PIP in older people in general. [9, 18, 19]. To date,
there has not been a systematic review that has assessed how
the tools are being utilised in studies of PIP in older people
with dementia. Given the higher number of co-morbidities
and the increased drug burden experienced by this group com-
pared with their non-cognitively impaired counterparts [2,
20], a systematic review of studies utilising tools to identify
PIP in this cohort is an essential addition to the literature.
The aims of the review were:
1. To describe and summarise studies that have used a pub-
lished tool to identify PIP in people with dementia.
2. To report the prevalence of PIP and the medications iden-
tified as inappropriate in the included studies.
3. To describe the potential advantages, disadvantages or
complications of using the tools as identified by the au-
thors of the included studies.
Methods
The review was conducted according to the recommendations
set out in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [21].
Search strategy
A systematic search of the published peer-reviewed literature
and grey literature was conducted in April 2016. Literature
search strategies were developed using Medical Subject
Headings (MeSH) terms and text words around the topic of
dementia and inappropriate prescribing (The Appendix
Table 3 documents the full search strategy for Medline,
which was then adapted as appropriate for the other
databases). The following databases were searched: Medline
(Ovid), CINAHL Plus (EBSCO Host), Embase (Ovid),
PsycInfo (Ovid), Social Science Citation Index (Web of
Science) and the Cochrane Library (Wiley). There was no
restriction by year of publication. Searches were also conduct-
ed for grey literature using the following online databases:
OpenGrey, Grey Literature Report, Mednar, BASE and the
National Database for Ageing Research. A search of the
reference lists of retrieved papers was also conducted.
Table 1 lists the criteria for including studies in the systematic
review.
Data extraction, assessment and analysis
Two authors (DH and JB) independently reviewed the titles and
abstracts against the inclusion criteria. The full papers for refer-
ences that appeared to meet the criteria, or those for which there
was uncertainty, were retrieved for independent review by both
authors (DH and JB).Where there was disagreement about which
papers should be included, these were resolved by discussion.
The third author (UM) was available to resolve any ongoing
disagreements about inclusion. Where there were any exclusions
of full-text articles, the reason for exclusion was recorded (Fig. 1).
A standardised list of data to be extracted was created,
based on the aims and objectives of the review. The data
extracted were authors and year of publication, study aims
and objectives, study design, tools used, study setting, sample
size, demographic data, prevalence of polypharmacy, preva-
lence of PIP, most commonly prescribed PIP medications,
summary of main findings, strengths and limitations of the
tools and author’s conclusions. The data were extracted inde-
pendently by two of the authors (DH and JB) and any dis-
agreements resolved by discussion.
Quality assessment
Critical appraisal of the included papers was conducted using
the Hawker Tool [22]. The papers were independently
assessed by two of the authors (DH and JB) for methodolog-
ical quality and risk of bias. Studies were weighted but were
not to be excluded from the review on the basis of quality. This
tool was chosen because it has been designed to be used to
assess study quality for multiple study designs and has been
used for this purpose in previous systematic reviews [23–28].
The Hawker Tool assesses the reporting of a study in the
following areas: abstract and title, introduction and aims,
method and data, sampling, data analysis, ethics and bias,
findings and results, transferability and reliability, and impli-
cations and usefulness. Each of the nine areas is given a score
of either 1 (very poor), 2 (poor), 3 (fair) or 4 (good) which
gives a total overall score out of 36 for each paper [22].
Results
Search results
The search of biomedical databases identified 4597 papers,
and a further 712 were identified through the grey literature
search and hand searching of reference lists. After removal of
duplicates, there were 3626 unique studies. After eligibility
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screening, 47 full-text articles were assessed for inclusion, of
which 26 papers were included in the review (Fig. 1).
Quality assessment
The Hawker score for the included studies ranged from
22/36 [29, 30] to 36/36 [31, 32]. The median total score
was 29/36. Previous reviews using the Hawker Tool [22]
have set a cut-off of 20/36 or above to indicate a study
that is of a fair to good quality [25, 27]. On this basis,
all 26 studies would be classed as at least fair quality.
Overall, the studies scored lowest for reporting on Ethics
and Bias and also Transferability and Reliability
(Appendix Table 4).
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Fig. 1 PRISMA flow chart of the
literature search
Table 1 Inclusion and exclusion criteria
Study
characteristic
Include Exclude
Design Randomised/non-randomised controlled trials/intervention studies—any
Observational Studies—any
Qualitative studies—any
Tool development papers
Participants Studies that include people with a diagnosis of/suspected dementia—either the whole sam-
ple or as part of a study with a control group (e.g. mild cognitive impairment or no
dementia)
Studies that do not recruit a sample of
people with dementia
Studies of people with mild cognitive
impairment only
Setting Any—community, primary care, secondary care, tertiary care, social care, palliative care
Country/language Any
Intervention/tool Any tool developed for identifying potentially inappropriate prescribing including
dementia-specific or non-disease-specific tools
Date of
publication
Any
Eur J Clin Pharmacol
Characteristics of the included studies
Table 2 outlines the characteristics of the 26 included studies
including study design, tools used to identify potentially inap-
propriate prescribing, country, setting, participants and sum-
mary of results. Twenty-five studies were observational that
used at least one tool to measure the prevalence of PIP [2, 5,
29, 31–52]. One study was a non-randomised evaluation of an
intervention to improve medication management [30].
Across all 26 studies, 26,534 participants were recruited, of
which 21,285 (80%) had dementia or cognitive impairment, 968
(4%) had mild cognitive impairment and 4281 (16%) were non-
cognitively impaired controls. A total of 17,928 of the participants
were female (68%). Mean age ranged from 72.5 [2] to 86.8 [5].
Number of medications and the prevalence
of polypharmacy
Ten studies reported a range for number of medications pre-
scribed; this was from 0 to 22 [5, 32, 33, 35, 37, 46–48, 50, 51].
Mean number of medications was reported in 19 studies [2, 5,
29–32, 34, 36, 37, 40–43, 45–48, 50, 51] and ranged from 4
[50] to 14 [31]. When comparing the mean number of medica-
tions between those with and without dementia, results were
mixed, with two studies reporting a significantly lower mean
number of medications in those with cognitive impairment [43,
45] and, by contrast, two studies reporting a significantly higher
number in those with cognitive impairment [2, 41].
Eleven studies reported the prevalence of polypharmacy as
the percentage of participants taking ≥ 5 medications [2,
30–32, 35, 38, 40, 42, 44, 46, 51]. The prevalence of
polypharmacy ranged from 25% [38] to 98% [51] for people
with dementia or cognitive impairment (see Table 2).
Prevalence of PIP
The prevalence of PIP was reported as the percentage of the
cohort taking at least one potentially inappropriate medica-
tion. For people with dementia, this ranged from 14% [44]
to 74% [31]. For non-cognitively impaired controls, the prev-
alence ranged from 11% [2] to 44% [43] (see Table 2).
In studies comparing the prevalence of PIP between those
with and without cognitive impairment or dementia, two stud-
ies found a significantly higher prevalence in those with de-
mentia [2, 39], three found a significantly lower prevalence in
those with dementia [41, 43, 47], and two found no significant
difference between the groups [31, 37].
The most commonly prescribed potentially inappropriate
medications were anxiolytic–hypnotics and anticholinergic
medications [2, 29, 31–33, 35, 37–39, 43–47, 50, 51]. Rates
of anticholinergic prescription ranged from 6% [45] to 46%
[32]. Rates of anxiolytic–hypnotic (including benzodiaze-
pines) use ranged from 5% [43] to 38% [51]. Other commonly
prescribed potentially inappropriate medications included
lipid-lowering medications [34, 48, 49] and antiplatelets
[34], oestrogens [36, 40, 41, 47], non-steroidal anti-inflamma-
tory drugs (NSAIDs) [5, 36, 47], antipsychotics [5] and proton
pump inhibitors [5].
The use of a tool to identify potentially inappropriate
prescribing
The Beers criteria [11–13] were the most commonly used of the
tools (Table 2). Thirteen out of the 16 studies that used the Beers
criteria did not apply the full tool. Of these, seven studies only
used the list of potentially inappropriate medications for older
people in general [29, 40–42, 45, 47, 52] and four applied only
the disease-specific part of the tool [33, 35, 38, 39]. Two studies
were unable to apply the full criteria as some medications were
unavailable in the countries that the studies were located [43, 46].
Three of the five studies using the Holmes criteria [57]
defined potentially inappropriate medications as only those
drugs on the ‘Never Appropriate’ list [38, 48, 49], one defined
potentially inappropriate medications as those on the ‘Never
Appropriate’ and ‘Rarely Appropriate’ lists [34] and one ap-
plied the whole criteria to their dataset [50]. Three of the
studies using the STOPP START [15] applied only the
STOPP criteria to their data [2, 5, 35].
Eight studies utilised at least one additional tool to identify
potentially inappropriate medications, five of which used a pub-
lished tool to identify anticholinergic medications [2, 32, 35, 39,
46]. Four studies used an additional list of potentially inappro-
priate medications devised by the authors [39, 42, 43, 46].
Problems using the tools
Seventeen studies identified potential issues associated with
using the tools [5, 30, 31, 33, 35, 38, 40–50]. One problem
identified was the consensus methods used to develop the tools
meant the risk benefit profile was subjective [33, 38]. In addi-
tion, the NORGEP criteria did not include drugs that may be
inappropriate for specific co-morbidities and as such may have
resulted in an underestimation of the prevalence of PIP [44].
Also, the type of data collected would determine the extent
to which the criteria could be applied. For example, one study
could only apply 31 out of the 65 STOPP criteria [15] because
of a lack of diagnostic information available in the notes [5].
The authors note that this lack of information could in itself
contribute to inappropriate prescribing [5].
Two versions of the Beers criteria [11, 12] were not easily
applied in countries outside of the USA because some medica-
tions listed were not available in other countries [42, 43, 45, 46].
One study compared the Beers criteria [12] and the Laroche List
[59] and found a higher prevalence of PIP using the latter [42].
The authors argue this demonstrates the Laroche List [59] is
better suited to a European population. In addition, another study
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identified that the Beers criteria [12] needed to be updated to
include more sedative and anticholinergic medications [40].
The Holmes criteria [57] may need more validating and
updating. The authors of the studies using this tool highlighted
that some medications may have been placed in the wrong
category given more recent evidence for their use in older
adults with advanced dementia [38, 48–50].
Discussion
This is the first systematic review to describe how tools de-
signed to identify PIP were being used in studies of older
people with dementia. In this review, the majority of included
studies (21 out of 26) were published from 2010 onwards,
perhaps reflecting an increasing awareness of the importance
of rational prescribing in this cohort of older patients.
The Beers criteria [11–13] were the most commonly used of
all the tools. With the exception of the STOPP START [15] and
the Holmes criteria [57], all the other tools used were developed
as country-specific versions of the Beers criteria. The review
demonstrates that even when the same tool was used, how the
tools were applied varied across studies. For example, several
studies did not apply the disease-specific part of the Beers
criteria to identify PIMs for people with dementia [29, 40–42,
45, 47, 52] mainly due to a lack of diagnostic or prescribing
information. This may have underestimated the prevalence of
PIP. Three studies compared the prevalence of PIP between
those with and without dementia and reported a significantly
lower prevalence in the dementia group [41, 47, 52]. Prevalence
rates for PIP in people with dementia may have been higher had
the disease-specific tools been applied. Prevalence under-
reporting was also found in a systematic review of studies using
the Beers criteria to identify PIP in older people [61]. When
designing a study, researchers need to consider what medication
and diagnostic data they will need to collect to fully apply their
chosen tool. This will reduce the risk of underestimating the
prevalence of PIP. There may also be scope for reviewing
how hospital, general practice and care homes record prescrib-
ing and diagnostic information, how this can be improved and
whether better recording of such information would lead to
improvements in prescribing.
Polypharmacy and inappropriate medication use
This review found that prevalence of polypharmacy in those
with dementia (25% to 98%) is high. This range of
polypharmacy prevalence is similar to that in previous studies
of polypharmacy in older people with dementia [62–66].
The prevalence of PIP in people with dementia ranged
from 13 to 74% and from 11 to 39% for people without de-
mentia. This is despite over 20 years of research into inappro-
priate prescribing in older people [10, 67, 68].
We were unable to reach a conclusion as to whether the prev-
alence rates of PIP are significantly higher in people with demen-
tia compared with people without cognitive impairment. Some
studies reported a higher rate of PIP in those with dementia [2,
39], while some reported the opposite effect [41, 43, 47] and
others reported no difference between the two groups [31, 37].
The different findings may be partly due to the different tools
used, how they were applied and variations in study design.
The most commonly prescribed potentially inappropriate
medications reported were sedatives and anticholinergic med-
ications. This is despite strong evidence that these medications
should be avoided because of their adverse cognitive effects in
people with dementia [69–72]. Only two studies correlated the
use of such medications by severity of dementia [31, 38]
which is surprising given the known risks associatedwith their
use. Future research should focus on the use of medications
with strong central nervous system (CNS) effects in people
with dementia and how this changes over the disease course.
Oestrogen was another commonly prescribed PIM despite an
increased risk of endometrial and breast cancer, and there is
some evidence it may increase cognitive decline in postmen-
opausal women [12, 41, 73, 74].
Advantages and disadvantages of the tools
The included studies highlighted some potential advantages
and disadvantages of the tools. One study identified that both
the STOPP START and the Beers criteria were internationally
recognised and well-validated tools, making them the pre-
ferred choice despite any potential disadvantages [35].
However, medication or diagnostic information needed to
apply sections of the criteria was not always available. For
example, studies using the Beers criteria, or tools adapted
from them, were unable to obtain information about dose or
diagnosis in patient notes which meant parts of the tools were
not used [40–42, 47]. In addition, one study had to exclude
more than half of the STOPP criteria due to a lack of avail-
ability of diagnostic and other clinical information in patient
notes [5]. It may be that the STOPP START criteria would be
more useful in a clinical setting than in research. It could be
used to support medication reviews in the presence of the
patient where the necessary clinical information needed to
fully utilise the tool can be obtained. The STOPP START is
one of the few tools designed to identify both overuse and
underuse of medications and as such would enable a compre-
hensive review of a patient’s medications compared with other
tools such as the Beers criteria.
Studies utilising the STOPP STARTcriteria [15] to identify
PIMs excluded the START component and therefore did not
identify cases where there was under-use of medications [2, 5,
35]. Given that people with dementia may be at risk of under-
treatment, including poor pain control [3, 4], it is important to
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consider this aspect of potentially inappropriate prescribing in
both clinical and research settings.
As new evidence becomes available, the tools need regular
updating but this may not always be done. The Holmes criteria
[57] were found to be in need of updating. In four of the
studies using the Holmes criteria [34, 38, 48, 49], one of the
most commonly prescribed PIMs were acetylcholinesterase
inhibitors. These medications were placed in the Never
Appropriate category of the Holmes criteria [57] because at
the time of the criteria’s development there was little evidence
to support their use for moderate to severe dementia [48].
However, recent evidence suggests they may continue to have
a positive effect in later stages of the disease [75, 76] and this
has resulted in changes to clinical guidelines on use of
donepezil in people with dementia [41].
One study highlighted that the Beers criteria [12] were not
comprehensive enough, particularly regarding anticholiner-
gics and sedatives [40]. Subsequent versions of the Beers
criteria [13, 14] include a list of anticholinergic and sedative
medications that should be avoided particularly in older peo-
ple with dementia or delirium. However, this list is not as
comprehensive as the tools developed specifically to identify
anticholinergic medications [55, 56, 77] which were used by
some of the included studies in this review [2, 32, 35, 39, 46].
In choosing an appropriate tool to identify PIP for a re-
search study, pragmatic consideration needs to be given to
its comprehensiveness, how up to date it is and whether the
tool can be fully utilised given the available drug and medical
history information of the cohort under investigation.
Quality of the included studies
This review found that the reporting of the studies asmeasured
by the Hawker Tool was generally good, with most studies
scoring well overall. However, most of the studies could have
better reported ethical and bias considerations and discussed
generalisability of their findings in more detail. Better
reporting of studies is crucial to being able to judge their
potential for bias and the reliability of results.
The generalisability of the findings of this review may be
limited by the marked heterogeneity of the methodologies
employed in the included studies, for example, the variations
in which tools were used and how they were utilised and the
variations in study population and settings.
Twenty-five out of the 26 included studies were observa-
tional in design, and of these, only three were prospective
cohort studies [39, 45, 48] while the remaining studies collect-
ed cross-sectional or retrospective data. The benefit of a pro-
spective design is the reduced risk of bias and confounding.
However, prospective studies conducted over many years run
the risk of a high rate of attrition which the authors of one
study noted was a limitation of their work [39]. The only
intervention study [30] utilised an uncontrolled Bbefore and
after^ design which risks an overestimation of the effect of the
intervention. In addition, four studies may have had low sta-
tistical power due to a small sample size of less than 150
which may have affected the reliability of their results [5,
29, 30, 33]. More robust study designs that limit the opportu-
nity for confounding or bias are needed in this area of re-
search. A similar observation was made in a previous review
of studies using the STOPP START criteria [78].
Strengths and limitations of the review
To date, this is the first systematic review of studies using tools
to identify PIP in people with dementia and was designed
using robust methodology [21]. A previous literature review
[79] covered a similar topic; however, it was not a rigorously
conducted systematic review. In addition, this review is more
up to date and includes studies published as recently as 2016.
There are several potential limitations. Two papers by the
same authors were included despite the potential for some
overlap of participants in the two studies [40, 41]. Although
the participants in each study appeared to be distinct, it was
not entirely clear whether some of the participants may have
taken part in both studies; therefore, the demographic data
may be slightly overestimated.
A meta-analysis on the extracted data for prevalence of, or
factors associated with, PIP was not possible due to the het-
erogeneity of the included studies in terms of methodology,
participants, tools used and the application of those tools.
There was heterogeneity of reporting data such as mean/
median number of medications and prevalence of
polypharmacy across the included studies. When reported in
the original articles, the mean or median number of medica-
tions are presented in Table 2.
Implications for practice
This review has highlighted the need for a more standardised
approach in the use of the tools that have been developed to
identify PIP in older people with dementia. Tools identifying
PIP cannot replace clinical judgement, and a medication iden-
tified as potentially inappropriate using such tools may subse-
quently be found to be appropriate following a full clinical
assessment. Therefore, the use of such tools should be seen
as a guide to aid clinical decision-making.
The use of more than one tool in several of the included
studies suggests that current tools need to be more compre-
hensive to ensure that all potentially inappropriate medica-
tions are included. Consideration of whether the use of
anxiolytic–hypnotic and anticholinergic medications is appro-
priate is particularly important given their effects on older
people in general, but especially in people with dementia.
As a minimum, clinicians should consider focusing on such
CNS-PIP medications as a priority for deprescribing in this
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cohort. One of the published anticholinergic tools such as the
Drug Burden Index [56] or the Anticholinergic Cognitive
Burden Scale [77] may prove a useful guide to aid decision-
making when reviewing a patient’s medications.
When deciding which tool to use, consideration needs to be
given regarding what data will be needed to fully utilise the
tool, the location of use, whether this data can be obtained and
how to obtain it. In view that the tools have many differences,
and none are universally applicable, two (or more) complemen-
tary tools (preferably recently updated) might be needed for a
thorough assessment of PIP; using a tool which identifies both
PIPs and omitted drugs would increase the clinical impact.
Future research
This review has demonstrated that rates of inappropriate pre-
scribing and polypharmacy amongst older people with de-
mentia are high. In particular, rates of anticholinergic and sed-
ative medication use are high despite evidence of the risks
associated with their use in people with dementia. Future re-
search should focus on why this is the case and how the pre-
scribing of these medications can be reduced.
As PIP is associated with the number of medications a patient
is taking [5, 33, 37, 38, 41, 42, 52], future studies could focus on
identifying a standardised way to present drug exposure that
includes a definition of excessive polypharmacy (e.g. the use of
≥ 10 medications) and the use of concomitant medications as
well as overuse or underuse of medications. Furthermore, given
the known risks associated with the use of medications such as
anticholinergics and sedatives in people with dementia, studies
that correlate potentially inappropriate use of central nervous
system medications with disease severity are needed.
Conclusions
This review found that the application of tools varied consider-
ably. This may in part explain the variations in prevalence of PIP
found across the studies. To be effective, they need to be regu-
larly updated andmay not yet be comprehensive enough to iden-
tify all potentially inappropriate medications. The review also
demonstrated that despite long standing awareness of inappropri-
ate prescribing, prevalence of PIP remains high for both older
people in general and older people with dementia in particular.
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Appendix
Table 3 Medline search strategy
1 Inappropriate prescribing (exp)
2 Inappropriate medication (exp)
3 Medication errors (exp)
4 Suboptimal prescribing
5 Polypharmacy (exp)
6 Over-prescribing
7 Under-prescribing
8 Misprescribing
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 Dementia (exp)
11 9 and 10
12 Screening tool
13 Criteria
14 12 or 13
15 ACOVE Quality Indicators
16 Austrian Criteria
17 Beers Criteria
18 Holmes Criteria
19 Laroche Criteria
20 Lindblad’s List
21 Malone’s List
22 McLeod Criteria
23 NCOA Criteria
24 NORGEP
25 Rancourt Criteria
26 START Criteria
27 STOPP Criteria
28 STOPP START Criteria
29 Priscus List
30 Zhan Criteria
31 Maio Criteria
32 KPC Criteria
33 Lechevallier Criteria
34 New Mexico Criteria
35 CMS List
36 Improving prescribing in the elderly tool
37 Matsumura Alert System
38 Sloane List
39 FORTA Criteria
40 Cantrill Indicators
41 Lipton’s Tool
42 Medication Appropriateness Index
43 PMDRP
44 Barenholtz Levy
45 Hamdy Criteria
46 Owen’s Steps
47 Robertson’s Flow Charts
48 Australian Prescribing Indicators
49 Brown Model
50 Oborne’s Prescribing Indicators
51 TIMER tool
52 Geriatric Medication Algorithm
53 Kaiser Permanente Model
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Table 3 (continued)
5-
4
Medications Management Outcome Monitor
5-
5
Prescribing Optimisation Method
5-
6
ARMOUR Tool
5-
7
15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or
27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or
39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or
51 or 52 or 53 or 54 or 55 or 56
5-
8
14 or 57
5-
9
9 and 58
6-
0
11 or 59
Note: papers retrieved from the final search on the bottom line of the
table: dementia and PIP (11) or PIP and screening tool/criteria/specific
tools (59)
Table 4 Quality assessment scores for included papers
Study Abstract Intro Method Sampling Data analysis Ethics and bias Findings/
results
Transferability Implications Total
Alzner et al. [31] 4 4 4 4 4 4 4 4 4 36/36
Andersen et al. [2] 4 3 4 4 3 3 3 3 2 29/36
Barton et al. [33] 4 4 4 3 2 1 3 3 4 28/36
Bosboom et al. [32] 4 4 4 4 4 4 4 4 4 36/36
Brunet et al. [30] 4 3 2 2 2 1 3 2 3 22/36
Chan et al. [29] 4 3 2 2 3 2 2 2 2 22/36
Colloca et al. [34] 4 3 4 4 4 4 4 3 3 33/36
Cross et al. [35] 4 4 4 4 4 3 3 4 4 34/36
Epstein et al. [36] 4 4 3 2 3 1 4 2 3 26/36
Fiss et al. [37] 4 2 3 3 3 3 3 2 4 27/36
Hanlon et al. [38] 4 3 4 2 3 3 4 2 4 29/36
Koyama et al. [39] 4 3 4 4 4 4 4 4 4 35/36
Lau et al. [40] 3 4 4 4 4 3 3 2 3 30/36
Lau et al. [41] 3 3 4 4 4 3 3 4 3 31/36
Montastruc et al. [42] 4 3 3 2 4 3 4 2 3 28/36
Nygaard et al. [43] 4 3 4 3 4 2 3 2 2 27/36
Oesterhus et al. [44] 4 4 4 4 4 4 4 4 3 35/36
Parsons et al. [5] 4 4 4 3 3 3 4 3 4 32/36
Raivio et al. [45] 4 4 3 3 3 2 3 3 2 27/36
Somers et al. [46] 3 4 3 3 2 2 3 3 2 25/36
Thorpe et al. [47] 4 4 4 3 4 2 4 3 4 32/36
Tija et al. [48] 4 4 4 3 4 2 4 4 3 32/36
Tija et al. [49] 4 3 3 4 4 3 3 4 4 32/36
Toscani et al. [50] 1 3 4 3 3 2 3 3 4 26/36
Von Ranteln et al. [51] 4 3 2 2 2 2 3 2 3 23/36
Zuckerman et al. [52] 4 3 3 3 4 2 3 3 2 27/36
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